Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Adam Kashishian"'
Autor:
Haritha Mathsyaraja, Benjamin Wolf, Chari Cortez, Adam Kashishian, Alison Karst, Madelyn Cueva, Min Wang, Kathleen S. Keegan, Jennifer Cain
Publikováno v:
Cancer Research. 82:2079-2079
Tumor cells employ mechanisms to evade anti-tumor immune responses that can include the downregulation or silencing of cytosolic nucleic acid sensing pathway components to dampen Type I IFN signaling. It has been documented that genomic instability a
Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation
Autor:
Julie Farand, Jeffrey E. Kropf, Peter Blomgren, Jianjun Xu, Aaron C. Schmitt, Zachary E. Newby, Ting Wang, Eisuke Murakami, Ona Barauskas, Jawahar Sudhamsu, Joy Y. Feng, Anita Niedziela-Majka, Brian E. Schultz, Karen Schwartz, Serge Viatchenko-Karpinski, Dmytro Kornyeyev, Adam Kashishian, Peidong Fan, Xiaowu Chen, Eric B. Lansdon, Michael O. Ports, Kevin S. Currie, William J. Watkins, Gregory T. Notte
Publikováno v:
ACS Med Chem Lett
[Image: see text] We describe the discovery of three structurally differentiated potent and selective MTH1 inhibitors and their subsequent use to investigate MTH1 as an oncology target, culminating in target (in)validation. Tetrahydronaphthyridine 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a8664fe5cf60201d9c5d872c2fbdf25
https://europepmc.org/articles/PMC7074220/
https://europepmc.org/articles/PMC7074220/
Publikováno v:
Cancer Research. 78:2371-2371
Spleen tyrosine kinase (SYK), a non-receptor protein tyrosine kinase, is an important mediator of immune receptor signaling in B cells, mast cells, neutrophils, and macrophages. SYK is expressed in 90% of AML blasts and has been reported to be is con
Autor:
Jerry Evarts, Gary Phillips, Joshua Kaplan, David Koditek, Kathleen S. Keegan, Adam Kashishian, Zhi-Hua Cui, Joseph Therrien, Jennifer Treiberg, Bart Phillips, Latesh Lad, Eve-Irene Lepist, Jayaraman Chandrasekhar, Leena Patel, Anella Yahiaoui, Stephane Perreault, Jia Hao, Mary E. McGrath, Thomas Kenney
Publikováno v:
Journal of medicinal chemistry. 60(4)
Phosphoinositide 3-kinase (PI3K) β signaling is required to sustain cancer cell growth in which the tumor suppressor phosphatase and tensin homolog (PTEN) has been deactivated. This manuscript describes the discovery, optimization, and in vivo evalu
Autor:
Adam Kashishian, S. Jeffrey Dixon, Stephen M. Sims, Natsuko Tanabe, Alexey Pereverzev, Ryan P.P. Shugg, Kamal D. Puri, Frank R. Jirik, Brian J. Lannutti, Ashley Thomson, Bart H. Steiner
Publikováno v:
Journal of Biological Chemistry. 288:35346-35357
Phosphatidylinositol 3-kinases (PI3K) participate in numerous signaling pathways, and control distinct biological functions. Studies using pan-PI3K inhibitors suggest roles for PI3K in osteoclasts, but little is known about specific PI3K isoforms in
Autor:
Kamal D. Puri, Carmen Ip, Adam Kashishian, Gary Phillips, Sandy Koppenol, Musong Kim, Jennifer Treiberg, Armando G. Villaseñor, Jayaraman Chandrasekhar, Stephane Perreault, Kristen Forseth, Leena Patel, Mary E. McGrath, Bart H. Steiner, Joseph Therrien, John R. Somoza, Aaron C. Haran, David Koditek, Latesh Lad, Eve-Irene Lepist, Jerry Evarts
Publikováno v:
Journal of medicinal chemistry. 59(19)
Aberrant signaling of phosphoinositide 3-kinase δ (PI3Kδ) has been implicated in numerous pathologies including hematological malignancies and rheumatoid arthritis. Described in this manuscript are the discovery, optimization, and in vivo evaluatio
Autor:
Adolfo A. Ferrando, Evgeni Efimenko, Mireia Castillo, Jianchung Chen, Kim De Keersmaecker, Dosh Whye, Valeria Tosello, Carlos Cordon-Cardo, Mary Ann Thompson, Adam Kashishian, Utpal P. Davé, Prem S. Subramaniam, Thomas G. Diacovo, Brian J. Lannutti
Publikováno v:
Cancer Cell. 21(4):459-472
SummaryConstitutive phosphoinositide 3-kinase (PI3K)/Akt activation is common in T cell acute lymphoblastic leukemia (T-ALL). Although four distinct class I PI3K isoforms (α, β, γ, δ) could participate in T-ALL pathogenesis, none has been implica
Autor:
Dave Johnson, Volker Diehl, Sarah A. Meadows, Adam Kashishian, Langdon L. Miller, Francisco Vega, Anas Younes, Brian J. Lannutti
Publikováno v:
Blood. 119:1897-1900
GS-1101 (CAL-101) is an oral PI3Kδ-specific inhibitor that has shown preclinical and clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. To investigate the potential role of PI3Kδ in Hodgkin lymphoma (HL), we screened 5 HL c
Autor:
Amy J. Johnson, Sarah E. M. Herman, Jeffrey W. Tyner, Sarah A. Meadows, Adam Kashishian, Bart Steiner, Brian J. Lannutti, Brian J. Druker, Kamal D. Puri, John C. Byrd, Neill A. Giese, Mike Deininger, Marc M. Loriaux, Roger G. Ulrich
Publikováno v:
Blood. 117:591-594
Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to promote malignant B-cell proliferation and survival. This provides a rationale for the development of small molecule inhibit
Autor:
Peng Yue, Stacey Tannheimer, Kathleen S. Keegan, Jia Y. Liu, Adam Kashishian, Sarah O. Meadows, Leslie Butterworth, Christophe Quéva, Li Li, Tom Kenney
Publikováno v:
Cancer Research. 75:2673-2673
Diffuse large B-cell lymphoma (DLBCL) is the largest lymphoma subtype representing approximately one-third of all cases of non-Hodgkin's lymphoma. Gene expression profiling showed that DLBCL can be stratified into activated B-cell (ABC) or germinal c